Oncolytics Biotech (ONCY) Set to Post Quarterly Earnings on Wednesday

Oncolytics Biotech (NASDAQ:ONCY) will likely be posting its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Oncolytics Biotech to post earnings of ($0.0539) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Oncolytics Biotech (NASDAQ:ONCY) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). On average, analysts expect Oncolytics Biotech to post ($0.29) EPS for the current fiscal year and ($0.22) EPS for the next fiscal year.

Oncolytics Biotech Trading Down 2.5%

Oncolytics Biotech stock opened at $0.39 on Wednesday. The stock has a fifty day moving average price of $0.65 and a 200 day moving average price of $0.86. Oncolytics Biotech has a 52 week low of $0.38 and a 52 week high of $1.30. The firm has a market capitalization of $51.14 million, a P/E ratio of -1.15 and a beta of 1.26.

Wall Street Analyst Weigh In

Several research firms have commented on ONCY. HC Wainwright lowered their price target on Oncolytics Biotech to $5.00 and set a “buy” rating for the company in a report on Wednesday, August 19th. Weiss Ratings lowered shares of Oncolytics Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, October 26th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $5.00.

About Oncolytics Biotech

Oncolytics Biotech Inc is a clinical-stage biotechnology company developing immunotherapies for cancer. The company’s lead product candidate is pelareorep, an investigational, intravenously delivered reovirus designed to selectively infect and destroy certain tumor cells while stimulating an immune response against cancer.

Oncolytics is evaluating pelareorep in combination with other cancer treatments, including chemotherapy, hormonal therapies and immune checkpoint inhibitors. Its research has focused primarily on breast cancer and gastrointestinal cancers, including pancreatic cancer, with development programs intended to assess the therapy’s potential across multiple tumor types.

Founded in 1998, Oncolytics Biotech is headquartered in Calgary, Alberta, and conducts clinical and corporate activities in North America and other regions through its research and development programs.